Form 4: HeartBeam Director Receives Significant Equity Awards

HeartBeam, Inc. Director Marga Ortigas-Wedekind was granted restricted stock units and stock options, aligning her interests with shareholders.

Summary

• Marga Ortigas-Wedekind, a Director of HeartBeam, Inc. (BEAT), reported changes in her beneficial ownership.
• She holds 112,293 shares of Common Stock directly and 16,824 shares indirectly.
• On July 11, 2025, she was granted 60,483 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock.
• These RSUs are scheduled to vest 100% on the earlier of July 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on her continued service as an Outside Director.
• On September 30, 2025, she was granted options to purchase 39,394 shares of Common Stock at an exercise price of $1.65 per share.
• These options vest in two tranches: one half on the three-month anniversary of the July 1, 2025 vesting commencement date, and the remaining half on the six-month anniversary of the same date.
• The options expire on July 1, 2035, and were issued from the Company's 2022 Equity Incentive Plan.
• Following these transactions, she beneficially owns 83,029 derivative securities (options) and 60,483 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive signal, indicating alignment of interests between management and shareholders and potential confidence in the company's future. It does not, however, provide direct insight into operational or financial performance.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The equity awards demonstrate continued commitment and confidence from a key board member in the company's future.

Future Outlook

The vesting schedules for the Restricted Stock Units (RSUs) and stock options indicate future milestones for the director's equity ownership, with RSUs vesting by July 11, 2026, or the 2026 annual meeting, and options vesting in two tranches based on a July 1, 2025 commencement date.

Industry Context

This filing is a standard disclosure of insider equity compensation, common across all industries, reflecting a company's practice of incentivizing its leadership through equity awards to align their performance with shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options for director compensation is a common practice in the biotechnology and medical device industry, aligning with typical executive and board compensation structures.
• The vesting schedules, tied to continued service, are standard mechanisms to retain key personnel and ensure long-term commitment, comparable to practices at companies like Medtronic or Boston Scientific.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units and stock options to Marga Ortigas-Wedekind, a Director of HeartBeam, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Increased alignment of the director's financial interests with shareholder value due to equity ownership.
• Employees: The use of an equity incentive plan for directors may signal a broader commitment to equity-based compensation, potentially impacting employee morale and retention.

Next Steps

• Vesting of Restricted Stock Units (RSUs) on the earlier of July 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
• Vesting of stock options on the three-month and six-month anniversaries of July 1, 2025.

Key Dates

Keywords

HeartBeam, BEAT, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Corporate Governance